Groupe la Francaise Has $3.92 Million Stake in Gilead Sciences, Inc. $GILD

Groupe la Francaise grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1,467.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,490 shares of the biopharmaceutical company’s stock after acquiring an additional 33,226 shares during the period. Groupe la Francaise’s holdings in Gilead Sciences were worth $3,918,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new position in Gilead Sciences in the 2nd quarter valued at $2,150,268,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new position in shares of Gilead Sciences in the first quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC acquired a new position in Gilead Sciences during the 2nd quarter worth about $238,083,000. Finally, Vanguard Group Inc. grew its holdings in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research reports. UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Royal Bank Of Canada upped their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Argus increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $130.65.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 135,757 shares of company stock worth $16,616,127 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $125.00 on Thursday. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market cap of $155.09 billion, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The business’s fifty day moving average is $120.53 and its 200-day moving average is $115.09.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the company posted $2.02 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.